Member Info for Thompi

Succinctly put Moab. TG2D is so desperate to spin a negative narrative that he misunderstood (deliberately ?) the RNS.

TG2D - you will have to re-read the RNS and try all over again.

Not getting involved in a slinging match Notrex. I respect your views on AVCT (and agree with many of them) but I stand by comments about you getting too personal with your abuse of ICE.

Notrex, I agree with Thorn. There is the standard ‘normal’ abuse on here - twat etc - but your comments towards ICE are becoming vindictive and too personal.

Has anyone had confirmation from Consilium that they have been ‘accepted’ to attend the AGM? I am still waiting for a reply.

Evening ICE, ref your post “…..I would expect a full update before the AGM especially on the 3w trials and possibly cohort 1 of the 2w trials…”

I hope you are right and I am sure we will some get some form of an update on the trials, but I guess it’s what you define as a “full update”. We may get an abridged version but CC reiterated in yesterday’s webinar that an update on the AVA6000 clinical data would be H2.

I’m not trying to be pedantic, but I also think that a chunk of the AGM may well be dedicated to ‘other matters’.

WAG, I didn’t get a notification but I logged into my account online (not via the HL app). The link should be on your home page account summary. It is at the right hand side of the page, there are some heading links, the first one is Secure Messages. The second one is Share Holder Meetings, click underneath it - View Shareholder Meetings and all the information is there. There is a list of resolutions and you will be able to place your voting instructions.

Hope you find it ok, but it is definitely there for me. It’s not particularly easy to find, I remembered it from voting last year.

Voting instructions are now on HL.

Ice, I agree raising funds in this environment is challenging. However, in late September the SP was around the £1.20 mark and many (including myself) were reassured when AS said regarding funding - “So, you know, we have plenty of optionality and that's always at the front of our minds as a board of directors, so don't worry about that.” (September interim results). And yet here we now are - a badly managed and leaked raise at only 50p, sentiment at rock bottom, the SP floundering in the low 40’s and no meaningful demonstration of any II’s significant investment.. So I can understand the anger and frustration felt by some towards the senior management (who have been generously remunerated).

AS has fallen/been pushed on his sword. So perhaps it is time to move on, but the options performance targets and bonuses have to be more closely aligned to the SP and shareholder interests from now on.

Thanks GMCC. And I agree PL75, I much prefer a realistic and considered timeline than AS’s over optimistic approach.

I will add to that Fevertreeman - perhaps also ask IG why there hasn’t been an RNS officially announcing the results yet?

I am very encouraged by the progress of the company this year, but it would be good to finally get the results and the outlook.

Change from February’s TP note of AVA6000 potentially to market by end 2026, to today’s note - “Avacta's first targeted chemotherapy could find its way to patients as early as 2028.”

Thanks GMCC & BV (and also for the link that worked). The patents mentions hair follicle regeneration. Interesting

Morning Gmcc, as our resident AffyXell expert, I’m just wondering if you have come across EPI Biotech in your research? AffyXell are listed as an applicant on one of their patents. I hope this link works.

WO2024054006 NOVEL GENOMIC SAFE HARBOR AND USE THEREOF

(If the link doesn’t work it was on patentscope.wipo.int)

Wyn, I am coming up to my second anniversary as an AVCT investor, so the LFT was slightly before my time. However, I am confident that William Tap, Professor Banerji and the other oncologists involved with the trial provide independent and external validation of AVA6000.

AS’s over optimistic timelines are very frustrating, as are the lack of comms. I hope there is an announcement soon regarding the dosing of the third patient in C2 of the two-weekly trial.

Regarding the three later cohorts (5-7) in the three weekly study - if they help establish an optimal dose for the greater good of future patients, then I still see them as a positive.

Thorn, perhaps the “defiant name calling” is a reaction to how often (and how negatively) you post on a share you are not invested in - 7 posts on Saturday, 11 posts on Friday……

Sometimes I think you make a fair point, but the amount of posts are relentless and it p***es people off.

Swazer, you post “Your entitlement is off the scale.” Oh, the irony, pomposity and lack of self awareness when it was preceded by “You should be addressing me as Sir and showing me the respect I deserve.”

Your conceit is staggering. It almost makes Oph look humble. But well done you, or should I call you “Sir”…

My thanks too BV for emailing CC.

Tim, my wife frequently loses the car in the supermarket car park - why has this not been highlighted as a major risk. I’m worried that she always manages to find her way home.

Flipping heck Oxygen - she’s only been in the CEO job five minutes, it’s a bit premature to worry about CC leaving just yet.

Fair comment PL75, apologies for my post.